Article

Real-world Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents

2023-06-20

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> The efficacy of the BNT162b2 vaccine in pediatrics was assessed by randomized trials before the Omicron variant’s emergence. The long-term durability of vaccine protection in this population during the Omicron period remains limited. <h4>Objective</h4> To assess the effectiveness of BNT162b2 in preventing infection and severe diseases with various strains of the SARS-CoV-2 vir...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 27491b19-0b07-585d-a5c8-f1608aded15f
DOI: 10.1101/2023.06.16.23291515

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Real-world Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and AdolescentsDOI 10.1101/2023.06.16.23291515Read

Effectiveness of BNT162b2 COVID-19 Vaccination in Children Aged 5–17 Years in the United StatesSemantic proximity Read

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron VariantSemantic proximity Read

Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 YearsSemantic proximity Read

Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after the third dose of BNT162b2 in healthy adolescentsSemantic proximity Read

Safety of the BNT162b2 mRNA COVID-19 Vaccine in Children below 5 Years (CoVacU5) – an Investigator-Initiated Retrospective Cohort StudySemantic proximity Read

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in ArgentinaSemantic proximity Read

Effectiveness of BNT162b2 and CoronaVac against pediatric COVID-19-associated hospitalization and moderate-to-severe diseaseSemantic proximity Read

Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVacSemantic proximity Read

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 Vaccines Against Hospitalisations Among Children and Adolescents During the Omicron Outbreak in ArgentinaSemantic proximity Read

Immunogenicity and reactogenicity of SARS-CoV-2 mRNA and inactivated vaccines in healthy adolescentsSemantic proximity Read

Sex differences in symptoms following the administration of BNT162b2 mRNA Covid-19 Vaccine in Children below 5 Years of age in Germany (CoVacU5): a retrospective cohort studySemantic proximity Read

Immunologic response, Efficacy, and Safety of Vaccines Against COVID-19 Infection in Children and Adolescents Aged 2 – 21 years old: A Systematic ReviewSemantic proximity Read